根据名称进行药物检索

Cipro Iv Minibags与QT间期延长

Cipro Iv Minibags与QT间期延长安全配伍检测的结果。

检测结果:

Cipro Iv Minibags <> QT间期延长

现实性: 23.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种伴发疾病互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

种药物已经报道了延长夸脱间隔的心电图在一些患者。夸脱的延长可能会加强风险的心律失常包括室性心动过速、心室纤维性颤动，以及心动de扭转性. 风险似乎最大，与格列沙星和司(这两个是不再销售的，在美国)，尽管心血管疾病发病率和死亡原因是脱延长，也有报道很少与其他人喜欢沙星、左氧氟沙星、环丙沙星、和氧氟沙星。报告的案件主要发生在患者的高龄、心脏病、电解质紊乱，和/或潜在的医疗问题，他们是接收伴随药物已知的延长夸脱的时间间隔。治疗种药物，应避免在患者与已知的夸脱的延长和/或未校正的电解质失调症(低钾或镁血症)，并在接受治疗的患者同时与IA类或三級心律失常药。谨慎使用心電圖监测，建议在患者与其他致心律失常的条件，如临床显着缓、充血性心力衰竭、急性心肌局部缺血和心房纤维性颤动。作为脱延长可以是一个浓度依赖的作用，这是很重要的推荐剂量或灌输价这些药物不被超过，特别是在患有肾和/或肝功能损害。

来源

"Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.
Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000): 658-66
Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8
"Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.
Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001): 361-2
Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004): 77-9
Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996): 499-503
Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6
Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72
Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996): 161-7
Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004): 464-73
"Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.
Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72
Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002): 861-3
Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996): 350-1
"Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.
Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124
Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6
Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20
Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999): 528-9
Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001): 23
Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003): 292-303
"Product Information. Tequin (gatifloxacin)" Bristol-Myers Squibb, Princeton, NJ.
Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64
Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77
Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001): 32-7
Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001): 46-7
Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999): 1171-81
Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19